Skip to main content

Advertisement

Table 3 Relationships between serum sCD40L and clinicopathological characteristics of PDAC, compared with CA19-9 in the validation dataset

From: Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

  sCD40L CA19-9
γs(p- value) γs(p- value)
Gender (Male: Female) -0.046 (0.740) -0.213 (0.126)
Age (≤40, > 40 & ≤60, > 60) 0.076 (0.581) -0.181 (0.194)
T-stage (T1, T2, T3 ,T4) 0.194 (0.156) 0.095 (0.501)
Node metastasis (N0, N1) -0.146 (0.289) 0.362 (0.008)
Distant metastasis (M0, M1) 0.294(0.030) 0.425 (0.002)
Overall stage (I, II, III, IV) 0.319 (0.017) 0.431 (0.001)
Size (≤2 cm, > 2 cm & ≤5 cm, > 5 cm) 0.035 (0.801) 0.179 (0.201)
Unresectability* 0.342 (0.011) 0.269 (0.051)
  1. sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; PDAC, pancreatic ductal adenocarcinoma.
  2. γs, Spearman’s correlation coefficient.
  3. p < 0.05 (two-tailed) was considered to be statistically significant.
  4. Statistically significant values are given in bold type.
  5. *A tumor is defined as unresectable when a tumor invades celiac axis or superior mesenteric artery (T4, N0-1, M0, stage III), or metastasizes to distant sites (T1-4, N0-1, M1, stage IV).